论文部分内容阅读
1980年11月～1983年7月,美国马里兰州对1114名6～13周龄的婴儿进行疫苗试服,观察他们对口服脊髓灰质炎疫苗(OPV)及强效脊髓灰质炎灭活疫苗(IPV)的血清学应答。将婴儿随机分为三组。第1组口服OPV,剂量为Ⅰ型8×10~5半数组织培养感染量(TCID_(50)),Ⅱ型10~5TCID_(50),Ⅲ型5×10~5TCID_(50)。第2组接种法国生产的强效IPV(IPV A),Ⅰ型D抗原含量为24～38,Ⅱ型为3.6～6.5,Ⅲ型为28～36。第3组接种加拿大生产的强效IPV(IPV B),Ⅰ型含D抗
From November 1980 to July 1983, 1114 infants 6 to 13 weeks of age in the United States of America were tested for their vaccine against oral poliovirus (OPV) and potent polio inactivated vaccine (IPV ) Serological response. The infants were randomly divided into three groups. The first group received oral OPV at a dose of 8 × 10 ~ 5 for half of the tissue culture infection (TCID 50), 10 ~ 5 TCID 50 for type Ⅱ and 5 × 10 5 TCID 50 for type Ⅲ. Group 2 was vaccinated with the potent IPV (IPV A) produced in France. The type I D antigen content was 24-38, type II 3.6-6.5 and type III 28-36. Group 3 was vaccinated with a potent IPV (IPV B) produced in Canada, Type I with D-Antibody